Analysed BIOAFFINITY TECHNOLOGIEW-27 (BIAFW:NASDAQ) News Sources
New Case Study: bioAffinity Technologies’ CyPath® Lung Diagnostic Supports Physician’s Assessment, Prompts Follow-Up Imaging and Defers Unnecessary Biopsy
14-04-2026
yahoo.com
bioAffinity Technologies’ CyPath® Lung to Be Featured at Cleveland Clinic Annual "Advances in Early Lung Cancer Detection" Symposium April 16
07-04-2026
yahoo.com
bioAffinity Technologies’ CyPath® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026
01-04-2026
yahoo.com
bioAffinity Technologies to Host Live Virtual Physician Roundtable on Integrating CyPath® Lung into Pulmonary Practice
25-03-2026
yahoo.com
New Case Study: bioAffinity Technologies’ CyPath® Lung Provides Actionable Results and Helps Patient Avoid Costly, Invasive Procedures
17-03-2026
yahoo.com
bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung Cancer Test
25-02-2026
yahoo.com
New Case Study Highlights Ability of bioAffinity Technologies’ CyPath® Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer
19-02-2026
yahoo.com
What is the current price of BIOAFFINITY TECHNOLOGIEW-27 (BIAFW:NASDAQ)?
The current price of BIOAFFINITY TECHNOLOGIEW-27 (BIAFW:NASDAQ) is $0.3267.
BIOAFFINITY TECHNOLOGIEW-27 (BIAFW:NASDAQ) absolute price change since previous trading day?
The absolute price change of BIOAFFINITY TECHNOLOGIEW-27 (BIAFW:NASDAQ) since the previous trading day is $-0.0033.
BIOAFFINITY TECHNOLOGIEW-27 (BIAFW:NASDAQ) percentage price change since previous trading day?
The percentage price change of BIOAFFINITY TECHNOLOGIEW-27 (BIAFW:NASDAQ) since the previous trading day is -1%.
What is the most recent average sentiment score for BIOAFFINITY TECHNOLOGIEW-27 (BIAFW:NASDAQ)?
The most recent average sentiment score for BIOAFFINITY TECHNOLOGIEW-27 (BIAFW:NASDAQ) is 81 out of 100.
What is the most recent average sentiment for BIOAFFINITY TECHNOLOGIEW-27 (BIAFW:NASDAQ)?
The most recent sentiment for BIOAFFINITY TECHNOLOGIEW-27 (BIAFW:NASDAQ) is .
SEC-8K** Filing Available For BIOAFFINITY TECHNOLOGIEW-27 (BIAFW:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.